Status:
UNKNOWN
N- Homocysteinylated Huntingtin in Huntington's Disease
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Huntington Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: 1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), 2. symptomatic HD individuals wit...
Detailed Description
Prospective inclusions of 32 subjects with 24 symptomatic HD patients and 8 presymptomatic HD patients.Rationale: This is a pilot study in humans. Over a period of 2 years, the potential recruitment s...
Eligibility Criteria
Inclusion
- Patient with the symptomatic or presymptomatic Huntington's disease gene (CAG \>= 36)
- Molecularly confirmed Huntington's disease
- Patient 18 years of age and older
- Person affiliated to or benefiting from a social security assurance
Exclusion
- Person deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1
- Pregnant woman, parturient or nursing mother
- Women of childbearing potential who do not have effective contraception
- Intellectual deterioration preventing the understanding of research
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT05225051
Start Date
April 1 2022
End Date
May 1 2023
Last Update
March 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.